MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

MeiraGTx Holdings plc stock surges after a major Eli Lilly partnership boosts funding and pipeline. Click for my updated look ...

ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will deliver ...

Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated ...

For the first time, scientists have managed to restore central vision loss from an irreversible age-related eye condition via ...

MCO-010, an optogenetic therapy, demonstrated long-term safety and improved quality of life in patients with retinitis ...

A groundbreaking electronic eye implant has offered a ray of hope to patients suffering from age-related macular degeneration ...

A tiny chip, smart glasses and months of training are rewriting what blindness means for older people with failing central ...

Xelafaslatide is an investigational first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal ...

With the darker months approaching, drivers could face serious difficulties when travelling with bright headlights dazzling ...

Detailed price information for Stoke Therapeutics Inc (STOK-Q) from The Globe and Mail including charting and trades.